The Ministry of Industry and Trade of the Russian Federation has announced the launch of a new support measure for the Russian biopharmaceutical industry. According to TASS, the agency plans to create a program to subsidize manufacturers’ expenses for conducting Phase III clinical trials.
Launch Timeline and Selection Mechanism
The draft of the corresponding regulatory act is currently in the final stages of interdepartmental coordination. The document is expected to be officially submitted to the Russian Government shortly. The preparation process for launching the program will begin this year.
“This year, we plan to select candidates for the subsidy, and the actual compensation payments will begin in 2027.”
— Press Service of the Russian Ministry of Industry and Trade
Support Conditions: Focus on Original Drugs
The subsidy program aims to support the development of innovative medicines rather than generic copies. The new measure focuses exclusively on original, first-in-class drugs.
A key feature of the mechanism is funding based on the principle of compensation for achieved results. Budgetary support will only be available for projects where pharmaceutical companies have fully completed all necessary clinical trial stages and obtained a marketing authorization (registration certificate) to bring the drug to market.
Russian Market Dynamics
Minpromtorg believes that introducing this financial “cashback” tool will allow Russian companies to invest more actively in the development of original medicines. This initiative, announced by Minister Anton Alikhanov in January 2026, is being implemented amid the growing market position of local manufacturers.
According to the ministry, Russian pharmaceutical companies continue to increase their market share in monetary terms: by the end of 2025, this figure reached 45.9%. For comparison, in 2020, the share of Russian medicines in monetary terms was 34.9%.
